Literature DB >> 32538834

Becoming or Remaining Agitated: The Course of Agitation in People with Dementia Living in Care Homes. The English Longitudinal Managing Agitation and Raising Quality of Life (MARQUE) Study.

Louise Marston1,2, Gill Livingston3,4, Anne Laybourne3, Claudia Cooper3,4.   

Abstract

Care home residents with dementia often have accompanying agitation. We investigated agitation's course at 5 time-points in 1,424 people with dementia over 16 months in 86 English care homes. We categorized baseline agitation symptoms on the Cohen-Mansfield Agitation Inventory (CMAI) into none (CMAI = 29; 15%), subclinical (CMAI = 30-45; 45%), or clinically-significant (CMAI > 45; 40%). 88% of those with no agitation at baseline remained free of clinically-significant agitation at all follow-ups. Seventy percent of those exhibiting clinically-significant agitation at baseline had clinically-significant agitation at some follow-ups. Over a 16-month observation period, this study finds many care home residents with dementia never develop clinically significant agitation and interventions should be for treatment not prevention.

Entities:  

Keywords:  Agitation; dementia; neuropsychiatric symptoms; nursing homes

Mesh:

Year:  2020        PMID: 32538834     DOI: 10.3233/JAD-191195

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials.

Authors:  Kathy Y Liu; Anya Borissova; Jansher Mahmood; Thomas Elliott; Melanie Knowles; Peter Bentham; Suzanne Reeves; Robert Howard
Journal:  Alzheimers Dement (N Y)       Date:  2021-03-30

2.  Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.

Authors:  Sube Banerjee; Juliet High; Susan Stirling; Lee Shepstone; Ann Marie Swart; Tanya Telling; Catherine Henderson; Clive Ballard; Peter Bentham; Alistair Burns; Nicolas Farina; Chris Fox; Paul Francis; Robert Howard; Martin Knapp; Iracema Leroi; Gill Livingston; Ramin Nilforooshan; Shirley Nurock; John O'Brien; Annabel Price; Alan J Thomas; Naji Tabet
Journal:  Lancet       Date:  2021-10-23       Impact factor: 79.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.